Company: SheMed
CEO & President: Olivia Ferro and Chloe Ferro
Website: https://shemed.co.uk/
About SheMed
Here’s a version tailored specifically for the Health Tech World Awards. It stays under 500 words, focuses on company impact rather than founder biographies, and avoids apostrophes, quotation marks, 3x3cut3, and executive.
SheMed was founded in 2024 to address a longstanding gap in healthcare by delivering personalised metabolic and weight management care designed specifically for women. While obesity, hormonal conditions, and metabolic disorders affect millions across the United Kingdom, many women continue to experience delayed diagnoses, fragmented care, and treatment pathways that do not fully consider female biology. SheMed was created to change that through a technology enabled, clinician led model that combines diagnostics, personalised treatment, and ongoing clinical support.
From the beginning, SheMed chose a different approach than many digital weight loss providers. Every patient completes comprehensive health screening and at home blood testing before treatment begins. Licensed clinicians review each patients metabolic health, cardiovascular risk, liver and thyroid function, medical history, and treatment goals before developing an individual care plan. Rather than focusing solely on prescribing medication, SheMed integrates GLP 1 therapies into a broader programme centred on long term health outcomes and continuous clinical oversight.
Building this model required overcoming several challenges. The rapid growth of GLP 1 medications created unprecedented demand while also increasing concerns around patient safety, appropriate prescribing, and inconsistent standards of care. SheMed invested in building the clinical infrastructure necessary to deliver personalised treatment safely at scale, balancing innovation with rigorous clinical governance. The company also developed technology that allows patients to complete consultations, diagnostics, treatment planning, and ongoing monitoring through a seamless digital experience.
The impact has been significant. In just two years, SheMed has grown to serve more than 100000 women across the United Kingdom and has become one of the fastest growing female founded health technology companies in Europe. During the past year, the company raised 50 million dollars at a 1 billion dollar valuation and launched one of the largest female focused GLP 1 programmes in the country. Its Weightloss Programme study is currently under review with a major medical journal, contributing new evidence to a field where women have historically been underrepresented in clinical research.
SheMed has also helped reshape the conversation around women’s health by demonstrating that digital healthcare can combine accessibility with clinical depth. Its model places diagnostics, clinician oversight, education, and personalised care at the centre of treatment rather than treating medication as a standalone solution. As the market continues to evolve with new therapies such as oral GLP 1 medications, SheMed continues to expand access to evidence based care while setting a higher standard for safety, personalisation, and long term patient outcomes within the HealthTech industry.
Want to find out what TechRound can do for your business?
